Brief: Hookipa Announces Positive Phase 1, 2 Plans For HB-200 Program For Treatment Of Advanced Head And Neck Cancers
05/06/2022 14:27
June 5 (Reuters) - HOOKIPA Pharma Inc HOOK.O :
* HOOKIPA ANNOUNCES POSITIVE PHASE 1 DATA AND PHASE 2 PLANS
FOR
HB-200 PROGRAM FOR TREATMENT OF ADVANCED HEAD AND NECK CANCERS
AT ASCO
* HOOKIPA PHARMA- ALTERNATING 2-VECTOR THERAPY SHOW SUPERIOR
ANTIGEN-SPECIFIC T CELL RESPONSES, ROBUST ANTI-TUMOR ACTIVITY,
SIMILAR TOLERABILITY VERSUS. SINGLE-VECTOR THERAPY
Source text for Eikon: ID:nGNX7Dv4KF
Further company coverage: HOOK.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Hookipa Pharma
See all newsBrief: Hookipa Pharma Announces Sale Of Oncology Assets To Neotrail Therapeutics
Brief: Hookipa Pharma Announces Intention To Voluntarily Delist And Deregister Its Common Stock
Hookipa Pharma Inc Expected To Post A Loss Of $1.04 A Share: Earnings Preview
Brief: Poolbeg Pharma Says Hookipa Terminated Discussions On Proposed Merger
HOOKIPA Pharma Inc. (“HOOKIPA”) Statement regarding potential combination for Poolbeg Pharma plc (“Poolbeg”)